Haemoglobin-based oxygen carriers: Research and reality towards an alternative to blood transfusions

Blood Transfusion

Volumn 8, Issue SUPPL. 3, 2010, Pages

  Mozzarelli, Andrea ^a   Ronda, Luca ^a   Faggiano, Serena ^a   Bettati, Stefano ^a   Bruno, Stefano ^a  

^a UNIVERSITY OF PARMA   (Italy)

Author keywords

Haemoglobin; Oxygen therapy; Red blood cells; Transfusion

Indexed keywords

2,3 DIPHOSPHOGLYCERIC ACID; DIASPIRIN CROSSLINKED HEMOGLOBIN; HEMOGLOBIN; HEMOSPAN; HEMOXIMER; LACTIC ACID; POLYMERIZED HEMOGLOBIN; SULFHEMOGLOBIN; UNCLASSIFIED DRUG;

BLOOD STORAGE; BLOOD TRANSFUSION; BLOOD VOLUME; CLINICAL TRIAL; ERYTHROCYTE; HEMOGLOBINOPATHY; HUMAN; OXYGEN TRANSPORT; REVIEW;

BLOOD SUBSTITUTES; BLOOD TRANSFUSION; HEMOGLOBINS; HUMANS; OXYGEN;

EID: 78049404205     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2010.010S     Document Type: Review

References (70)

1. Napolitano LM, Kurek S, Luchette FA, et al. Clinical practice guideline: red blood cell transfusion in adult trauma and critical care. Crit Care Med 2009; 37(12): 3124-57.
2. Bonaventura J. Clinical implications of the loss of vasoactive nitric oxide during red blood cell storage. Proc Natl Acad Sci U S A 2007; 104(49): 19165-6.
3. Bennett-Guerrero E, Veldman TH, Doctor A, et al. Evolution of adverse changes in stored RBCs. Proc Natl Acad Sci U S A 2007; 104(43): 17063-8.
4. Reynolds JD, Ahearn GS, Angelo M, et al. S-nitrosohemoglobin deficiency: a mechanism for loss of physiological activity in banked blood. Proc Natl Acad Sci U S A 2007; 104(43): 17058-62.
5. Zubair AC. Clinical impact of blood storage lesions. Am J Hematol 2010; 85(2): 117-22.
6. Buehler PW, Alayash AI. Toxicities of hemoglobin solutions: in search of in-vitro and in-vivo model systems. Transfusion 2004; 44(10): 1516-30.
7. Patel RP. Biochemical aspects of the reaction of hemoglobin and NO: implications for Hb-based blood substitutes. Free Radic Biol Med 2000; 28(10): 1518-25.
8. Isbell TS, Sun CW, Wu LC, et al. SNO-hemoglobin is not essential for red blood cell-dependent hypoxic vasodilation. Nat Med 2008; 14(7): 773-7.
9. Winslow RM. Blood Substitutes: Academic Press Inc., U.S., 2006.
10. Chang TMS. Artficial cells. London: World Scientific Publishing Co., 2007.
11. Campanini B, Bruno S, Raboni S, Mozzarelli A. Oxygen delivery via allosteric effectors of hemoglobin, blood substitutes and plasma expanders. In: Abraham D, editor. Burger's Medicinal Chemistry 6th edition: John Wiley and Sons, Inc., 2003:385-442.
12. Bruno S, Ronda L, Faggiano S, et al. Oxygen delivery via allosteric effectors of hemoglobin and blood substitutes. VII Ed. ed. Hoboken: John Wiley &Sons, Inc., 2010.
13. Silverman T, Weiskopf RB. Hemoglobin-based oxygen carriers. Anesthesiology 2009; 111: 946-963.
14. Goldstein J, Siviglia G, Hurst R, et al. Group B erythrocytes enzymatically converted to group O survive normally in A, B, and O individuals. Science 1982; 215(4529): 168-70.
15. Scott MD, Murad KL, Koumpouras F, et al. Chemical camouflage of antigenic determinants: stealth erythrocytes. Proc Natl Acad Sci U S A 1997; 94(14): 7566-71. (Pubitemid 27345356)
16. Zhu A, Leng L, Monahan C, et al. Characterization of recombinant alpha-galactosidase for use in seroconversion from blood group B to O of human erythrocytes. Arch Biochem Biophys 1996; 327(2): 324-9.
17. Murad KL, Mahany KL, Brugnara C, et al. Structural and functional consequences of antigenic modulation of red blood cells with methoxypoly(Ethylene Glycol). Blood 1999; 93(6): 2121-2127.
18. Ma F, Ebihara Y, Umeda K, et al. Generation of functional erythrocytes from human embryonic stem cell-derived definitive hematopoiesis. Proc Natl Acad Sci U S A 2008; 105(35): 13087-92.
19. Douay L, Lapillonne H, Turhan AG. Stem cells-a source of adult red blood cells for transfusion purposes: present and future. Crit Care Clin 2009; 25(2): 383-98.
20. Eaton WA, Henry ER, Hofrichter J, Mozzarelli A. Is cooperative oxygen binding by hemoglobin really understood? Nat Struct Biol 1999; 6(4): 351-8.
21. Bunn HF, Forget BG. Hemoglobin: Molecular, Genetic and Clinical Aspects. Philadelphia, PA: W. B. Saunders Company, 1986.
22. Monod J, Wyman J, Changeux J-P. On the nature of allosteric transitions: a plausible model. J. Mol. Biol. 1965; 12: 88-118.
23. Henry ER, Bettati S, Hofrichter J, Eaton W. A tertiary two-state allosteric model for hemoglobin. Biophys Chem 2002; 98: 149-164. (Pubitemid 34785988)
24. Viappiani C, Bettati S, Bruno S, et al. New insights into allosteric mechanisms from trapping unstable protein conformations in silica gels. Proc Natl Acad Sci U S A 2004; 101(40): 14414-9.
25. Yonetani T, Park SI, Tsuneshige A, et al. Global allostery model of hemoglobin. Modulation of O(2) affinity, cooperativity, and Bohr effect by heterotropic allosteric effectors. J Biol Chem 2002; 277(37): 34508-20.
26. Yeh LH, Alayash AI. Redox side reactions of haemoglobin and cell signalling mechanisms. J Intern Med 2003; 253(5): 518-26.
27. Sies H. Total antioxidant capacity: appraisal of a concept. J Nutr 2007; 137: 1493-1495.
28. Wallis JP. Nitric oxide and blood: a review. Transfus Med 2005; 15(1): 1-11.
29. Cooper CE. Nitric oxide and iron proteins. Biochim Biophys Acta - Bioenerg 1999; 1411: 290-309.
30. Vaughn MW, Huang KT, Kuo L, Liao JC. Erythrocytes possess an intrinsic barrier to nitric oxide consumption. J Biol Chem 2000; 275(4): 2342-8. (Pubitemid 30081991)
31. Liao JC, Hein TW, Vaughn MW, et al. Intravascular flow decreases erythrocyte consumption of nitric oxide. Proc Natl Acad Sci U S A 1999; 96(15): 8757-61.
32. Gladwin MT, Crawford JH, Patel RP. The biochemistry of nitric oxide, nitrite, and hemoglobin: role in blood flow regulation. Free Radic Biol Med 2004; 36(6): 707-17.
33. Olson JS, Foley EW, Rogge C, et al. NO scavenging and the hypertensive effect of hemoglobin-based blood substitutes. Free Radic Biol Med 2004; 36(6): 685-97.
34. Hess JR, MacDonald VW, Brinkley WW. Systemic and pulmonary hypertension after resuscitation with cell-free hemoglobin. J Appl Physiol 1993; 74(4): 1769-78.
35. Winslow RM. Current status of blood substitute research: towards a new paradigm. J Intern Med 2003; 253(5): 508-17.
36. Tsai AG, Vandegriff KD, Intaglietta M, Winslow RM. Targeted O2 delivery by low-P50 hemoglobin: a new basis for O2 therapeutics. Am J Physiol Heart Circ Physiol 2003; 285(4): H1411-9.
37. Tsai AG, Cabrales P, Manjula BN, et al. Dissociation of local nitric oxide concentration and vasoconstriction in the presence of cell-free hemoglobin oxygen carriers. Blood 2006; 108(10): 3603-10.
38. Gaucher-Di Stasio C, Paternotte E, Prin-Mathieu C, et al. The importance of the effect of shear stress on endothelial cells in determining the performance of hemoglobin based oxygen carriers. Biomaterials 2009; 30(4): 445-51.
39. Melkumyants AM, Balashov SA, Khayutin VM. Endothelium dependent control of arterial diameter by blood viscosity. Cardiovasc Res 1989; 23(9): 741-7.
40. Tsai AG, Acero C, Nance PR, et al. Elevated plasma viscosity in extreme hemodilution increases perivascular nitric oxide concentration and microvascular perfusion. Am J Physiol Heart Circ Physiol 2005; 288(4): H1730-9.
41. Salazar Vazquez BY, Wettstein R, Cabrales P, et al. Microvascular experimental evidence on the relative significance of restoring oxygen carrying capacity vs. blood viscosity in shock resuscitation. Biochim Biophys Acta 2008; 1784(10): 1421-7.
42. Looker D, Abbott-Brown D, Cozart P, et al. A human recombinant haemoglobin designed for use as a blood substitute. Nature 1992; 356(6366): 258-60.
43. Panetta G, Arcovito A, Morea V, et al. Hb(alphaalpha,betabeta): a novel fusion construct for a dimeric, four-domain hemoglobin. Biochim Biophys Acta 2008; 1784(10): 1462-70.
44. Graves PE, Henderson DP, Horstman MJ, et al. Enhancing stability and expression of recombinant human hemoglobin in E. coli: Progress in the development of a recombinant HBOC source. Biochim Biophys Acta 2008; 1784(10): 1471-9.
45. Doherty DH, Doyle MP, Curry SR, et al. Rate of reaction with nitric oxide determines the hypertensive effect of cell-free hemoglobin. Nat Biotechnol 1998; 16(7): 672-6.
46. Fronticelli C, Arosio D, Bobofchak KM, Vasquez GB. Molecular engineering of a polymer of tetrameric hemoglobins. Proteins 2001; 44(3): 212-22. (Pubitemid 32702230)
47. Fronticelli C, Koehler RC. Design of recombinant hemoglobins for use in transfusion fluids. Crit Care Clin 2009; 25: 357-371.
48. Bobofchak KM, Mito T, Texel SJ, et al. A recombinant polymeric hemoglobin with conformational, functional, and physiological characteristics of an in vivo O2 transporter. Am J Physiol Heart Circ Physiol 2003; 285(2): H549-61.
49. Chang TM. Modified hemoglobin-based blood substitutes: crosslinked, recombinant and encapsulated hemoglobin. Vox Sang 1998; 74 Suppl 2: 233-41.
50. Keipert P, Minkowitz J, Chang TM. Cross-linked stroma-free polyhemoglobin as a potential blood substitute. Int J Artif Organs 1982; 5(6): 383-5.
51. Vandegriff KD, McCarthy M, Rohlfs RJ, Winslow RM. Colloid osmotic properties of modified hemoglobins: chemically cross-linked versus polyethylene glycol surface-conjugated. Biophys Chem 1997; 69: 23-30. (Pubitemid 28010759)
52. Manjula BN, Tsai AG, Intaglietta M, et al. Conjugation of multiple copies of polyethylene glycol to hemoglobin facilitated through thiolation: Influence on hemoglobin structure and function. Protein J 2005; 24(3): 133-146.
53. Li D, Hu T, Manjula BN, Acharya SA. Extension arm facilitated PEGylation of alphaalpha-hemoglobin with modifications targeted exclusively to amino groups: functional and structural advantages of free Cys-93(beta) in the PEG-Hb adduct. Bioconjug Chem 2009; 20(11): 2062-70.
54. Caccia D, Ronda L, Frassi R, et al. PEGylation promotes hemoglobin tetramer dissociation. Bioconjug Chem 2009; 20(7): 1356-66.
55. Portoro I, Kocsis L, Herman P, et al. Towards a novel haemoglobin-based oxygen carrier: Euro-PEG-Hb, physico-chemical properties, vasoactivity and renal filtration. Biochim Biophys Acta 2008.
56. Iafelice R, Cristoni S, Caccia D, et al. Identification of the sites of deoxyhaemoglobin PEGylation. Biochem J 2007; 403(1): 189-96.
57. Vandegriff KD, Malavalli A, Wooldridge J, et al. MP4, a new nonvasoactive PEG-Hb conjugate. Transfusion 2003; 43(4): 509-16.
58. Johnson JL, Moore EE, Offner PJ, et al. Resuscitation of the injured patient with polymerized stroma-free hemoglobin does not produce systemic or pulmonary hypertension. Am J Surg 1998; 176(6): 612-7.
59. Kasper SM, Walter M, Grune F, et al. Effects of a hemoglobin-based oxygen carrier (HBOC-201) on hemodynamics and oxygen transport in patients undergoing preoperative hemodilution for elective abdominal aortic surgery. Anesth Analg 1996; 83(5): 921-7. (Pubitemid 26365401)
60. Asanuma H, Nakai K, Sanada S, et al. S-nitrosylated and pegylated hemoglobin, a newly developed artificial oxygen carrier, exerts cardioprotection against ischemic hearts. J Mol Cell Cardiol 2007; 42(5): 924-30.
61. Drobin D, Kjellstrom BT, Malm E, et al. Hemodynamic response and oxygen transport in pigs resuscitated with maleimide-polyethylene glycol-modified hemoglobin (MP4). J Appl Physiol 2004; 96(5): 1843-53.
62. Young MA, Riddez L, Kjellstrom BT, et al. MalPEG-hemoglobin (MP4) improves hemodynamics, acidbase status, and survival after uncontrolled hemorrhage in anesthetized swine. Crit Care Med 2005; 33(8): 1794-804.
63. Young MA, Riddez L, Kjellstrom BT, Winslow RM. Effect of maleimide-polyethylene glycol hemoglobin (MP4) on hemodynamics and acid-base status after uncontrolled hemorrhage in anesthetized swine: Comparison with crystalloid and blood. J Trauma 2007; 63(6): 1234-1244 10.1097/TA. 0b013e31815bd7b0.
64. Young MA, Malavalli A, Winslow N, et al. Toxicity and hemodynamic effects after single dose administration of MalPEG-hemoglobin (MP4) in rhesus monkeys. Transl Res 2007; 149(6): 333-42. (Pubitemid 46818159)
65. Cabrales P, Sun G, Zhou Y, et al. Effects of the molecular mass of tense-state polymerized bovine hemoglobin on blood pressure and vasoconstriction. J Appl Physiol 2009; 107(5): 1548-58.
66. Hess JR, Reiss RF. Resuscitation and the limited utility of the present generation of blood substitutes. Transfus Med Rev 1996; 10(4): 276-85.
67. Natanson C, Kern SJ, Lurie P, et al. Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death: a meta-analysis. Jama 2008; 299(19): 2304-12.
68. Greenburg AG, Pitman A, Pearce B, Kim HW. Clinical contextualization and the assessment of adverse events in HBOC trials. Artif Cells Blood Substit Immobil Biotechnol. 2008; 36: 477-486.
69. Estep T, Bucci E, Farmer M, et al. Basic science focus on blood substitutes: a summary of the NHLBI Division of Blood Diseases and Resources Working Group Workshop, March 1, 2006. Transfusion 2008; 48(4): 776-82.
70. Mozzarelli A. Hemoglobin-based oxygen carriers as blood substitutes. Biochim Biophys Acta 2008; 1784(10): 1363-4.